¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"essential melanotic mucosal hyperplasia"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • hyperplasia
    °ú´ÙÇü¼º, °úÇü¼º, Áõ½Ä(Áõ)
  • intravascular papillary endothelial hyperplasia
    Ç÷°ü³»À¯µÎ¸ð¾ç³»ÇǼ¼Æ÷Áõ½Ä
  • intraductal hyperplasia
    °ü³»Áõ½Ä
  • lentiginous melanocytic hyperplasia
    Èæ»öÁ¡¸á¶ó´Ñ¼¼Æ÷Áõ½ÄÁõ
  • lipoid adrenal hyperplasia
    ÁöÁúºÎ½Å°ú´ÙÇü¼º
  • lymphoid hyperplasia
    ¸²ÇÁ±¸Áõ½Ä
  • nodular hyperplasia
    °áÀý°ú´ÙÇü¼º
  • oral focal hyperplasia
    ÀԾȱ¹¼Ò»óÇÇÁõ½Ä
  • papillary endothelial hyperplasia
    À¯µÎ¸ð¾ç³»ÇǼ¼Æ÷Áõ½Ä
  • pseudocarcinomatous hyperplasia
    °ÅÁþ¾ÏÁ¾Áõ½Ä
  • pseudoepitheliomatous hyperplasia
    °ÅÁþ»óÇÇÁ¾Áõ½Ä
  • reactive nodular hyperplasia
    ¹ÝÀÀ¼º°áÀýÁõ½Ä
  • syringolymphoid hyperplasia
    ¶¡»ù°ü¸²ÇÁ¸ð¾çÁõ½Ä, ÇѰü¸²ÇÁ¼¼Æ÷Áõ½ÄÁõ
  • sebaceous hyperplasia
    ÇÇÁö»ùÁõ½Ä, ÇǺα⸧»ùÁõ½Ä
  • simple hyperplasia
    ´Ü¼øÁõ½Ä
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • lipoid adrenal hyperplasia
    ÁöÁúºÎ½Å°ú´ÙÇü¼º
  • lymphoid hyperplasia
    ¸²ÇÁ±¸Áõ½Ä
  • nodular hyperplasia
    °áÀý°ú´ÙÇü¼º
  • oral focal v hyperplasia
    ÀԾȱ¹¼Ò»óÇÇÁõ½Ä
  • papillary endothelial hyperplasia
    À¯µÎ¸ð¾ç³»ÇǼ¼Æ÷Áõ½Ä
  • pseudocarcinomatous hyperplasia
    °ÅÁþ¾ÏÁ¾Áõ½Ä
  • pseudoepitheliomatous hyperplasia
    °ÅÁþ»óÇÇÁ¾Áõ½Ä
  • reactive nodular hyperplasia
    ¹ÝÀÀ°áÀýÁõ½Ä
  • sebaceous hyperplasia
    ÇÇÁö»ùÁõ½Ä
  • syringolymphoid hyperplasia
    ¶¡»ù°ü¸²ÇÁ¸ð¾çÁõ½Ä
  • verrucous hyperplasia
    »ç¸¶±Í¸ð¾çÁõ½Ä
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • endothelial hyperplasia
    ³»ÇǼ¼Æ÷Áõ½Ä
  • epidermal hyperplasia
    Ç¥ÇÇÁõ½Ä
  • epithelial hyperplasia
    »óÇÇ Áõ½Ä(°úÇü¼º)
  • epithelial hyperplasia
    »óÇǼº Áõ½Ä(¡­ñòãÖ)
  • erythroid hyperplasia
  • essential
    º»Å¼ºÀÇ, Ư¹ß¼ºÀÇ, ÇʼöÀÇ, Áø
  • essential albuminuria
    º»Å¼º ´Ü¹é´¢.
  • essential amino acid
    Çʼö¾Æ¹Ì³ë»ê
  • essential amino acid
    Çʼö(ù±âÎ)¾Æ¹Ì³ë»ê
  • essential amino acids
    Çʼö¾Æ¹Ì³ë»ê.
  • essential anemia
    º»Å¼º ºóÇ÷.
  • essential anosmia
    Áø¼º ¹«Èİ¢Áõ, º»Å¼º Èİ¢¼Ò½Ç
  • essential bleeding
    Ư¹ß¼º ÃâÇ÷(¡­õóúì).
  • essential blepharospasm
    º»Å¼º¾È°Ë¿¬Ãà.
  • essential bradycardia
    º»Å¼º ¼­¸Æ(¡­ßïØæ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
SMRD stress-related mucosal damage
ET   1) Essential Thrombocytosis
  2) Embryo Transfer
EAA electroacupuncture analgesia; Epilepsy Association of America; essential amino acid; excitatory amin...
EACH essential access community hospital
EFA Epilepsy Foundation of America; essential fatty acid; extrafamily adoptee
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
EMC Essential Mixed Cryoglobulinemia
ET Essential Thrombocythemia
ET Essential Tremor
EAA Essential amino acid
EFAD Essential fatty acid deficiency
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • hyperplasia
    ºñÈÄ, Áõ½Ä, °úÇü¼º
    1. ±â´É Ç×ÁøÀ» À¯¹ß½ÃŰ´Â ÀÚ±ØÀ» ¹Þ¾ÒÀ» ¶§, ºÐ¿­ÀÌ °¡´ÉÇÑ ¼¼Æ÷°¡ ¼¼Æ÷ ºÐ¿­·Î ±× ¼ö°¡ Áõ°¡µÇ´Â °ÍÀ» ¸»Çϸç, °á°úÀûÀ¸·Î ±× Á¶Á÷À̳ª Àå±âµµ Ä¿Áö°Ô µÈ´Ù. ¹Ý¸é, ºñ´ë´Â ¼¼Æ÷ÀÇ Áõ½ÄÀÌ ¾øÀÌ ´Ü¼øÈ÷ ¼¼Æ÷ÀÇ Å©±â°¡ Ä¿Áö´Â °æ¿ì¸¦ À̸£´Â ¸»ÀÌ´Ù. 2. Á¤»ó ¼¼Æ÷ ¼ö°¡ Á¤»óÀûÀÎ ¹è¿­ »óÅ·ΠÁõ°¡ÇÏ´Â Á¶Á÷À̳ª ±¸Á¶¹°ÀÇ °ú¹ßÀ°.
  • hyperplasia of coronoid
    ±Ùµ¹±â °úÁõ½Ä
  • idiopathic fibrous gingival hyperplasia
    Ư¹ß¼º ¼¶À¯¼º Ä¡Àº Áõ½Ä
  • inflammatory gingival hyperplasia
    ¿°Áõ¼º Ä¡Àº Áõ½Ä
  • inflammatory hyperplasia
    ¿°Áõ¼º °úÇü¼º, ¿°Áõ¼º Áõ½Ä
    ¿°Áõ¿¡ ÀÇÇÏ¿© »ý±â´Â °úÇü¼º.
  • lentiginous melanocytic hyperplasia(ÈæÀÚ¼º ¸á¶ó´Ñ ¼¼Æ÷ Áõ½Ä)

    lentiglobus

    °ø ¸ð¾ç ¼öÁ¤Ã¼, ±¸Çü ¼öÁ¤Ã¼
    ¼öÁ¤Ã¼ Àü¸éÀÌ ±¸ÇüÀ¸·Î µÇ¾î¼­, ¼öÁ¤Ã¼ÀÇ °î¸éÀÌ °úÀåµÇ¾î º¸ÀÌ´Â °Í.
  • papillary hyperplasia
    À¯µÎ»ó Áõ½Ä, À¯µÎ Áõ½Ä
    1. ±¹¼ÒÀû ÀÚ±Ø, ºÒ·®ÇÑ ±¸°­ À§»ý, °¨¿°¿¡ ÀÇÇØ ¹ß»ýµÇ´Â »óÇÇÀÇ ´Ù¹ß¼º À¯µÎ»ó µ¹Ãâ. 2. ±¸°³ À¯µÎÁ¾ÁõÀ̶ó°íµµ ÇÑ´Ù. ÀÇÄ¡ ÇϹæ Á¡¸·¿¡ »ý±ä Ä­µð´ÙÁõÀº °æ±¸°³°¡ ÀÌ·¯ÇÑ Áõ½Ä¼º Á¶Á÷ ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â ÀڱؿøÀÌ µÈ´Ù.
  • paracortical lymphoid hyperplasia
    ºÎÇÇÁú¼º ¸²ÇÁ¾ç ¼¼Æ÷ Áõ½Ä
  • perforating hyperplasia
    õ°ø¼º Áõ½Ä
  • pseudocarcinomatous hyperplasia
    °¡¼º ¾ÏÁ¾¼º Áõ½Ä
  • salt-losing adrenal hyperplasia
    ¿°·ù ¼Ò½Ç¼º ºÎ½Å Áõ½ÄÁõ
  • total hyperplasia
    Àüü °ú´Ù Çü¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
essential thrombocytopenia A primary form of thrombocytopenia, in contrast to secondary forms that are associated with metastatic neoplasms, tuberculosis, and leukaemia involving the bone marrow, or with direct suppression of bone marrow by the use of chemical agents, or with other conditions.
(05 Mar 2000)
essential tremor <neurology> A tremor that is associated with purposeful movement or motor activity. Essential tremor is the most common form of tremor with no identifiable cause. Stress, anxiety and the use of stimulants (for example caffeine, decongestants) can often make the tremor worse. Treatment is usually not necessary for this benign condition.
(27 Sep 1997)
fatty acids, essential Fatty acids that cannot be synthesised by the human body and must be obtained from dietary sources, e.g., linoleic acids and linolenic acids.
(12 Dec 1998)
adrenal hyperplasia <pathology> A condition of diffuse enlargement of the adrenal glands.
Origin: Gr. Plassein = to form
(27 Sep 1997)
adrenal hyperplasia, congenital A group of inherited disorders of adrenal steroidogenesis, the physical expression of which varies with the sex of the patient, the severity of the congenital enzyme defect, and the age at which the defect makes its presence felt. The most common form, the simple virilizing form, is due to a 21-hydroxylase deficiency. There is also a salt-losing form (a more complete 21-hydroxylase deficiency), a hypertensive form (11-hydroxylase deficiency), a 17-hydroxylase deficiency form, a desmolase deficiency form, and a 3-beta-hydroxysteroid deficiency form.
(12 Dec 1998)
angiofollicular mediastinal lymph node hyperplasia Solitary masses of lymphoid tissue containing concentric perivascular aggregates of lymphocytes, occurring usually in the mediastinum or hilar region of young adults; similar changes have been reported outside the mediastinum and, if associated with interfollicular sheets of plasma cells, may progress to lymphoma or plasmacytoma.
Synonym: angiofollicular mediastinal lymph node hyperplasia, Castleman's disease.
(05 Mar 2000)
angiolymphoid hyperplasia with eosinophilia Solitary or multiple benign cutaneous nodules comprised of immature and mature vascular structures intermingled with endothelial cells and a varied infiltrate of eosinophils, histiocytes, lymphocytes, and mast cells.
(12 Dec 1998)
atypical melanocytic hyperplasia Proliferation of melanocytes showing nuclear atypicality, especially as scattered single cells high in the epidermis; interpreted by some pathologists as malignant melanoma in situ.
(05 Mar 2000)
basal cell hyperplasia Increase in the number of cells in an epithelium resembling the basal cells.
(05 Mar 2000)
benign giant lymph node hyperplasia Solitary masses of lymphoid tissue containing concentric perivascular aggregates of lymphocytes, occurring usually in the mediastinum or hilar region of young adults; similar changes have been reported outside the mediastinum and, if associated with interfollicular sheets of plasma cells, may progress to lymphoma or plasmacytoma.
Synonym: angiofollicular mediastinal lymph node hyperplasia, Castleman's disease.
(05 Mar 2000)
benign prostatic hyperplasia <urology> A benign enlargement of the prostate gland begins normally after age 50 years probably secondary to the effects of male hormones. If significant enlargement occurs, it may pinch off te urethra making urination difficult or impossible.
See: urinary retention.
Origin: Gr. Plassein = to form
(06 Aug 1998)
verrucous hyperplasia A non-invasive precursor of verrucous or squamous carcinoma of the oral mucosa, occurring in the elderly, characterised by sharp or blunt upward papillary projections of squamous epithelium.
(05 Mar 2000)
giant lymph node hyperplasia Large benign, hyperplastic lymph nodes. The more common hyaline vascular subtype is characterised by small hyaline vascular follicles and interfollicular capillary proliferations. Plasma cells are often present and represent another subtype with the plasma cells containing IgM and IgA.
(12 Dec 1998)
gingival hyperplasia Non-inflammatory enlargement of the gingivae produced by factors other than local irritation. It is characteristically due to an increase in the number of cells.
(12 Dec 1998)
cementum hyperplasia A regressive change of teeth characterised by excessive development of secondary cementum on the tooth surface. It may occur on any part of the root, but the apical two-thirds are most commonly affected.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á